Correlation Between Nephros and Guided Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Nephros and Guided Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nephros and Guided Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nephros and Guided Therapeutics, you can compare the effects of market volatilities on Nephros and Guided Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nephros with a short position of Guided Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nephros and Guided Therapeutics.

Diversification Opportunities for Nephros and Guided Therapeutics

-0.07
  Correlation Coefficient

Good diversification

The 3 months correlation between Nephros and Guided is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Nephros and Guided Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Guided Therapeutics and Nephros is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nephros are associated (or correlated) with Guided Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Guided Therapeutics has no effect on the direction of Nephros i.e., Nephros and Guided Therapeutics go up and down completely randomly.

Pair Corralation between Nephros and Guided Therapeutics

Given the investment horizon of 90 days Nephros is expected to generate 8.7 times less return on investment than Guided Therapeutics. But when comparing it to its historical volatility, Nephros is 3.48 times less risky than Guided Therapeutics. It trades about 0.02 of its potential returns per unit of risk. Guided Therapeutics is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  27.00  in Guided Therapeutics on November 28, 2024 and sell it today you would lose (16.00) from holding Guided Therapeutics or give up 59.26% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy99.79%
ValuesDaily Returns

Nephros  vs.  Guided Therapeutics

 Performance 
       Timeline  
Nephros 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Nephros are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong basic indicators, Nephros is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders.
Guided Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Guided Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's technical indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Nephros and Guided Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Nephros and Guided Therapeutics

The main advantage of trading using opposite Nephros and Guided Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nephros position performs unexpectedly, Guided Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Guided Therapeutics will offset losses from the drop in Guided Therapeutics' long position.
The idea behind Nephros and Guided Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Commodity Directory
Find actively traded commodities issued by global exchanges
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device